Patents by Inventor Jorge Alsina-Fernandez

Jorge Alsina-Fernandez has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Glucagon receptor agonists
    Patent number: 9764004
    Abstract: The present invention relates to compounds with an extended duration of action at the glucagon receptor as compared to native glucagon. Specifically provided are glucagon receptor agonists with modifications to the structure of native glucagon introduced to selectively agonize the glucagon receptor over an extended period of time.
    Type: Grant
    Filed: October 14, 2016
    Date of Patent: September 19, 2017
    Assignee: Eli Lilly and Company
    Inventors: Jorge Alsina-Fernandez, Tamer Coskun
  • Peptide compound for treatment of severe hypoglycemia
    Patent number: 9695225
    Abstract: A peptide compound useful in the treatment of hypoglycemia is described.
    Type: Grant
    Filed: December 11, 2014
    Date of Patent: July 4, 2017
    Assignee: Eli Lilly and Company
    Inventors: Jorge Alsina-Fernandez, Robert Chadwick Cummins, Lili Guo
  • Compound for treatment of severe hypoglycemia
    Patent number: 9688736
    Abstract: A peptide compound useful in the treatment of hypoglycemia is described.
    Type: Grant
    Filed: December 11, 2014
    Date of Patent: June 27, 2017
    Assignee: Eli Lilly and Company
    Inventors: Jorge Alsina-Fernandez, Robert Chadwick Cummins
  • GLUCAGON RECEPTOR AGONISTS
    Publication number: 20170112904
    Abstract: The present invention relates to compounds with an extended duration of action at the glucagon receptor as compared to native glucagon. Specifically provided are glucagon receptor agonists with modifications to the structure of native glucagon introduced to selectively agonize the glucagon receptor over an extended period of time.
    Type: Application
    Filed: October 14, 2016
    Publication date: April 27, 2017
    Inventors: Jorge Alsina-Fernandez, Tamer Coskun
  • GLUCAGON RECEPTOR AGONISTS
    Publication number: 20170114115
    Abstract: The present invention relates to compounds with an extended duration of action at the glucagon receptor as compared to native glucagon. Specifically provided are glucagon receptor agonists with modifications to the structure of native glucagon introduced to selectively agonize the glucagon receptor over an extended period of time.
    Type: Application
    Filed: October 14, 2016
    Publication date: April 27, 2017
    Inventors: Jorge Alsina-Fernandez, Tamer Coskun
  • Novel Compound for Treatment of Severe Hypoglycemia
    Publication number: 20160311881
    Abstract: The present invention provides a novel compound useful in the treatment of hypoglycemia.
    Type: Application
    Filed: December 11, 2014
    Publication date: October 27, 2016
    Inventors: Jorge Alsina-Fernandez, Robert Chadwick Cummins, Lili Guo
  • Novel Compound for Treatment of Severe Hypoglycemia
    Publication number: 20160311883
    Abstract: The present invention provides a novel compound useful in the treatment of hypoglycemia.
    Type: Application
    Filed: December 11, 2014
    Publication date: October 27, 2016
    Inventors: Jorge Alsina-Fernandez, Robert Chadwick Cummins
  • Novel Compound for Treatment of Severe Hypoglycemia
    Publication number: 20160311882
    Abstract: The present invention provides a novel compound useful in the treatment of hypoglycemia.
    Type: Application
    Filed: December 11, 2014
    Publication date: October 27, 2016
    Inventors: Jorge Alsina-Fernandez, Robert Chadwick Cummins, Lili Guo
  • GIP and GLP-1 co-agonist compounds
    Patent number: 9474780
    Abstract: The present invention relates to dual incretin peptide mimetic compounds that agonize receptors for both human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), and may be useful for treating type 2 diabetes mellitus (T2D).
    Type: Grant
    Filed: January 5, 2016
    Date of Patent: October 25, 2016
    Assignee: Eli Lilly and Company
    Inventors: Bengt Krister Bokvist, Tamer Coskun, Robert Chadwick Cummins, Jorge Alsina-Fernandez
  • GIP AND GLP-1 CO-AGONIST COMPOUNDS
    Publication number: 20160199438
    Abstract: The present invention relates to dual incretin peptide mimetic compounds that agonize receptors for both human glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1), and may be useful for treating type 2 diabetes mellitus (T2D).
    Type: Application
    Filed: January 5, 2016
    Publication date: July 14, 2016
    Inventors: Bengt Krister Bokvist, Tamer Coskun, Robert Chadwick Cummins, Jorge Alsina-Fernandez
  • Peptides and methods for their preparation and use
    Patent number: 8815811
    Abstract: The present invention is in the field of treatment of diabetes and relates to peptides that exhibit activity for both glucose-dependent insulinotropic peptide receptor (GIP-R) and glucagon-like peptide-1 receptor (GLP-1-R) and are selective over glucagon receptor (Gluc-R). Specifically provided are GIP analogs with amino acid substitutions introduced to modulate activity for both GIP-R and GLP-1-R and maintain selectivity over Gluc-R.
    Type: Grant
    Filed: March 23, 2011
    Date of Patent: August 26, 2014
    Assignee: Eli Lilly and Company
    Inventors: Jorge Alsina-Fernandez, Krister Bengt Bokvist, Lili Guo, John Philip Mayer
  • Homodimeric Proteins
    Publication number: 20140056893
    Abstract: This present invention relates to a homodimeric protein comprising fibroblast growth factor 21 (FGF21) and glucagon-like peptide (GLP-1), pharmaceutical compositions comprising the homodimeric protein, and methods for treating type 2 diabetes, obesity, dyslipidemia, and/or metabolic syndrome using such homodimeric protein.
    Type: Application
    Filed: August 15, 2013
    Publication date: February 27, 2014
    Applicant: Eli Lilly and Company
    Inventors: Tamer Coskun, Ryan James Darling, Malgorzata Donata Gonciarz, Jorge Alsina-Fernandez
  • Oxyntomodulin peptide analogue
    Patent number: 8415296
    Abstract: The present invention provides Oxyntomodulin peptide analogues useful in the treatment of diabetes and/or obesity.
    Type: Grant
    Filed: December 15, 2010
    Date of Patent: April 9, 2013
    Assignee: Eli Lilly and Company
    Inventors: Jorge Alsina-Fernandez, Wayne David Kohn
  • Oxyntomodulin peptide analogue
    Patent number: 8367607
    Abstract: The present invention provides an Oxyntomodulin peptide analogue useful in the treatment of diabetes and/or obesity.
    Type: Grant
    Filed: December 15, 2010
    Date of Patent: February 5, 2013
    Assignee: Eli Lilly and Company
    Inventors: Jorge Alsina-Fernandez, Wayne David Kohn
  • NOVEL PEPTIDES AND METHODS FOR THEIR PREPARATION AND USE
    Publication number: 20110237503
    Abstract: The present invention is in the field of treatment of diabetes and relates to peptides that exhibit activity for both glucose-dependent insulinotropic peptide receptor (GIP-R) and glucagon-like peptide-1 receptor (GLP-1-R) and are selective over glucagon receptor (Gluc-R). Specifically provided are GIP analogs with amino acid substitutions introduced to modulate activity for both GIP-R and GLP-1-R and maintain selectivity over Gluc-R.
    Type: Application
    Filed: March 23, 2011
    Publication date: September 29, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: Jorge ALSINA-FERNANDEZ, Krister Bengt BOKVIST, Lili GUO, John Philip MAYER
  • OXYNTOMODULIN PEPTIDE ANALOGUE
    Publication number: 20110152182
    Abstract: The present invention provides an Oxyntomodulin peptide analogue useful in the treatment of diabetes and/or obesity.
    Type: Application
    Filed: December 15, 2010
    Publication date: June 23, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: Jorge Alsina-Fernandez, Wayne David Kohn
  • OXYNTOMODULIN PEPTIDE ANALOGUE
    Publication number: 20110152181
    Abstract: The present invention provides Oxyntomodulin peptide analogues useful in the treatment of diabetes and/or obesity.
    Type: Application
    Filed: December 15, 2010
    Publication date: June 23, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: Jorge ALSINA-FERNANDEZ, Wayne David KOHN
  • Selective VPAC2 receptor peptide agonists
    Patent number: 7897573
    Abstract: The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.
    Type: Grant
    Filed: July 24, 2009
    Date of Patent: March 1, 2011
    Assignee: Eli Lilly and Company
    Inventors: Bengt Krister Bokvist, Lianshan Zhang, Jorge Alsina-Fernandez
  • SELECTIVE VPAC2 RECEPTOR PEPTIDE AGONISTS
    Publication number: 20100048460
    Abstract: The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.
    Type: Application
    Filed: February 26, 2007
    Publication date: February 25, 2010
    Inventors: Lianshan Zhang, Jorge Alsina-Fernandez
  • SELECTIVE VPAC2 RECEPTOR PEPTIDE AGONISTS
    Publication number: 20100009916
    Abstract: The present invention encompasses peptides that selectively activate the VPAC2 receptor and are useful in the treatment of diabetes.
    Type: Application
    Filed: July 24, 2009
    Publication date: January 14, 2010
    Inventors: BENGT KRISTER BOKVIST, LIANSHAN ZHANG, JORGE ALSINA-FERNANDEZ